Stock Track | Glaukos Plunges 13.82% in Pre-market as iDose Sales Growth Disappoints

Stock Track

Jan 14

Glaukos (GKOS) experienced a sharp pre-market decline of 13.82%, driven by investor concerns over weaker-than-expected sequential revenue growth for its iDose product in Q4 2025.

The medtech firm reported preliminary Q4 iDose sales of approximately $45 million, representing a 13% sequential increase from Q3. This growth fell short of some analysts' expectations, overshadowing the company's reaffirmed 2026 net sales guidance of $600 million to $620 million. Analysts noted that seasonal factors and a strong Q3 distorted the sequential growth trend, but the market reacted negatively to the slowdown.

Despite Glaukos maintaining its 2026 revenue outlook and reporting strong preliminary Q4 net sales of $143 million (up 36% YoY), the focus remained on the iDose performance, leading to the stock's pre-market plunge.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1189876267"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1189876267\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1189876267?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 18:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189876267","market":"us","top_or_hot":-1,"title":"Stock Track | Glaukos Plunges 13.82% in Pre-market as iDose Sales Growth Disappoints","media":"Stock Track","content":"<p>Glaukos (GKOS) experienced a sharp pre-market decline of 13.82%, driven by investor concerns over weaker-than-expected sequential revenue growth for its iDose product in Q4 2025.</p><p>The medtech firm reported preliminary Q4 iDose sales of approximately $45 million, representing a 13% sequential increase from Q3. This growth fell short of some analysts' expectations, overshadowing the company's reaffirmed 2026 net sales guidance of $600 million to $620 million. Analysts noted that seasonal factors and a strong Q3 distorted the sequential growth trend, but the market reacted negatively to the slowdown.</p><p>Despite Glaukos maintaining its 2026 revenue outlook and reporting strong preliminary Q4 net sales of $143 million (up 36% YoY), the focus remained on the iDose performance, leading to the stock's pre-market plunge.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Glaukos Plunges 13.82% in Pre-market as iDose Sales Growth Disappoints</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Glaukos Plunges 13.82% in Pre-market as iDose Sales Growth Disappoints\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-01-14 18:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Glaukos (GKOS) experienced a sharp pre-market decline of 13.82%, driven by investor concerns over weaker-than-expected sequential revenue growth for its iDose product in Q4 2025.</p><p>The medtech firm reported preliminary Q4 iDose sales of approximately $45 million, representing a 13% sequential increase from Q3. This growth fell short of some analysts' expectations, overshadowing the company's reaffirmed 2026 net sales guidance of $600 million to $620 million. Analysts noted that seasonal factors and a strong Q3 distorted the sequential growth trend, but the market reacted negatively to the slowdown.</p><p>Despite Glaukos maintaining its 2026 revenue outlook and reporting strong preliminary Q4 net sales of $143 million (up 36% YoY), the focus remained on the iDose performance, leading to the stock's pre-market plunge.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GKOS","symbol_name":"Glaukos Corp","start_time":0,"source_url":"","article_id":"1189876267","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189876267","pubTimestamp":1768385325,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Glaukos (GKOS) experienced a sharp pre-market decline of 13.82%, driven by investor concerns over weaker-than-expected sequential revenue growth for its iDose product in Q4 2025.The medtech firm...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GKOS":"Glaukos Corp"},"translate_title":"个股追踪|iDose销售增长令人失望，Glaukos盘前暴跌13.82%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GKOS":1},"content_text":"Glaukos (GKOS) experienced a sharp pre-market decline of 13.82%, driven by investor concerns over weaker-than-expected sequential revenue growth for its iDose product in Q4 2025.The medtech firm reported preliminary Q4 iDose sales of approximately $45 million, representing a 13% sequential increase from Q3. This growth fell short of some analysts' expectations, overshadowing the company's reaffirmed 2026 net sales guidance of $600 million to $620 million. Analysts noted that seasonal factors and a strong Q3 distorted the sequential growth trend, but the market reacted negatively to the slowdown.Despite Glaukos maintaining its 2026 revenue outlook and reporting strong preliminary Q4 net sales of $143 million (up 36% YoY), the focus remained on the iDose performance, leading to the stock's pre-market plunge.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}